These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26849078)

  • 1. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
    van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
    J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.
    Williams SM; Sumstad D; Kadidlo D; Curtsinger J; Luo X; Miller JS; McKenna DH
    Transfusion; 2018 Jun; 58(6):1458-1467. PubMed ID: 29532488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
    Lin SJ; Kuo ML
    Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
    Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
    Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
    Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW
    Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
    Decot V; Voillard L; Latger-Cannard V; Aissi-Rothé L; Perrier P; Stoltz JF; Bensoussan D
    Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
    Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V
    Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
    Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
    Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
    Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
    Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.